Elpiscience to Present ES002/ES004 Data at SITC 2019

September 19 , 2019 14:00

Shanghai September 19th 2019, Elpiscience Biopharma, Ltd., a clinical stage immuno-oncology company, announced that it will present data of anti-CD39 and anti-SIRPα antibodies, ES002 and ES004, at the upcoming SITC conference which will be held from Nov. 7-10, 2019 in Washington DC.

ES002 is a potentially best-in-class anti-CD39 therapeutic antibody, which reverses the suppressive tumor microenvironment and demonstrates strong anti-tumor efficacy in preclinical models. Mechanistic study revealing a dependency on innate immune cells in ES002-mediated anti-tumor response will be presented.

ES004 presentation will provide preclinical data on 2 unique anti-SIRPα antibodies, ES004-B4 and ES004-N4, which are CD47-SIRPα interaction “blocker” and “non-blocker”, respectively. Both antibodies greatly enhance macrophage-mediated tumor cell destruction, yet through different mechanisms of actions.

Details of the poster presentations are as follows:

Poster # P271

Title: Anti-SIRPalpha antibodies exert anti-tumor activity in both CD47-dependent and CD47-independent manners

Date: Friday, Nov. 8, 2019, 7:00 am - 8:00 pm

Poster # P790

Title: The anti-tumor activity of an anti-CD39 antibody (ES002) in a multiple myeloma model is dependent on NK cells

Date: Saturday, Nov. 9, 2019, 7:00 am - 8:30 pm